CTLA4 and prostate cancer: In addition, spontaneous prostate cancer in TRAMP transgenic mice, which is entirely checkpoint blockade resistant, responded dramatically to combination CTLA-4/PD-1 blockade when co-administered with the hypoxia-reducing agent TH-302.